looks as if big money's starting to give up the ghost. They did not do a significant debt buy back. Walsh needs to put some bullish news out to keep hope alive.
Get drug approved and have a soft launch; don't advertise; get GS to give a $3.00 a share price target and make sure the share price reaches that target; make sure the CEO does not cancel any of his automatic sells; keep your mouths shut and don't say anything. If this action does not result in a buy out or a spectacular second half on a REAL launch, somebody needs to get sued or fired. They have 6 months for redemption.
Look's the smart money is going to drive this until the ground. They know nothing is going to happen this year. Still could make a 50% return until then.
can't really blame them. This is a 2 billion company with nothing happening till next year.
They have always been right and still are. Al the biggest loser can have a seat and Nate who has lost other people's money can have a seat too. Educate us.
..what if they take into Japan with current results and fast track it. This trial indicated major benefit up to 30 hours. Restrict it's use to that time frame and study it too.
the treatment works at 24 hours, better standard of care than 6 hours. This will be the story Sunday and for next week.
"While the trial did not achieve the primary or component secondary endpoints, we believe the evidence indicating that patients who received MultiStem treatment early appeared to exhibit meaningfully better recovery is very important and promising," continued Dr. Van Bokkelen. "The results appear to confirm that our window of intervention with MultiStem therapy may extend well beyond the limits of current care. Additional key observations from the trial also appear consistent with key elements of our initial hypothesis. In particular, we are encouraged by the reduced mortality and lower incidence of infections, pulmonary events and life threatening adverse events among MultiStem-treated patients, as well as the limited biomarker data we have seen so far. We anticipate additional data and information from the study and will conduct further analyses to generate more insight about the potential for MultiStem treatment in this area."